Studying head and neck cancer to understand drug resistance
Part of Cancer clinical trials.
This trial collects tumor samples from people with head and neck squamous cell cancer to study why some cancers stop responding to standard treatments like cetuximab. The goal is to learn how resistance develops so better therapies can be found.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have squamous cell carcinoma of the head and neck
- If joining from past records: you were treated with cetuximab in the last 10 years
- If joining now or in the future: you have a head and neck squamous cell cancer diagnosis
- You or your legal representative must sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some head and neck cancers come back after treatment. It will test tumor tissue from people having surgery to see if certain proteins (mutant p53 and YAP) are linked to treatment resistance. Your participation could help researchers understand how to better treat these cancers in the future.
This trial studies the role of epigenetic marks in head and neck cancer to improve diagnosis and treatment. If you have been newly diagnosed with head and neck squamous cell carcinoma and have not yet received treatment, you may be eligible to participate.
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
This study collects blood and tumor tissue samples to analyze biological markers in patients with advanced head and neck squamous cell carcinoma before starting immunotherapy. The goal is to better understand how these markers relate to treatment response.
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
This trial studies whether giving cetuximab after prior immunotherapy can help people with head and neck squamous cell cancer shrink tumors or slow their growth. You may be eligible if you’ve already had a PD-1–based immunotherapy treatment, and you meet health and safety requirements.
Hear when a new Squamous Cell Tumors of the Head and Neck (HNSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.